About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases.
The Aegerion Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16441
Forward-Looking StatementsThis press release contains forward-looking statements, including statements regarding the completion and timing of Aegerion's proposed public offering of common stock. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond Aegerion's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, the risks and uncertainties include, among other factors: risks and uncertainties associated with market conditions and satisfaction of customary closing conditions related to the proposed offering, risks associated with Aegerion's ability to satisfy Aegerion's obligations to close the proposed offering and the risk that Aegerion will not use the proceeds from the offering in the manner contemplated. For additional disclosure regarding these and other risks, see the disclosure contained in Aegerion's public filings with the SEC (available on the SEC's website at http://www.sec.gov), including the "Risk Factors" section of Aegerion's Current Report on Form 8-K filed on January 10, 2013 and in the preliminary prospectus supplement and related prospectus relating to the proposed offering to be filed with the SEC. Aegerion undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
CONTACT: Aegerion Pharmaceuticals, Inc. Michael Lawless, VP, IR + 1 (857) 242-5028